A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects
This is a randomized, double-blinded, controlled Phase I three-arms study of CMAB807X administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807X Pre- and Post-change in Manufacturing Site, and Post-change CMAB807X versus Xgeva® #Denosumab# in healthy male subjects after a single dose
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of CMAB807X injection versus Angarvir in a single dose of Chinese adult healthy male subjects: a randomized, double-blind, parallel-controlled, phase I study
100 项与 CMAB-807X 相关的专利(医药)